EGFR and non-small cell lung carcinoma: A meta-analysis that evaluated the role of EGFR-TKIs as an adjuvant therapy for patients with completely resected EGFR-mutated NSCLC demonstrated that, compared to mono chemotherapy, early-generation EGFR-TKI monotherapy had a superior DFS benefit, but did not show a significant OS benefit, whereas treatment with EGFR-TKIs plus chemotherapy was associated with significantly longer DFS and OS compared to mono chemotherapy [53].